フッ化ピリミジン系薬剤とプラチナ系薬剤との併用療法に不応となった進行・再発食道癌に対するドセタキセル単独療法とパクリタキセル単独療法のランダム化比較第Ⅱ相試験（OGSG1201）

TRESBIEN (OGSG 2101): encorafenib, binimetinib and cetuximab for early recurrent stage II/III BRAF V600E-mutated colorectal cancer

Histology Classification Highlights Differences in Efficacy of S-1 versus Capecitabine, in Combination with Cisplatin, for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer with Measurable Disease

The Phase II Study of Panitumumab in Chemotherapy- Naïve Frail or Elderly Patients with RAS Wild-type Colorectal Cancer OGSG 1602 Final Results

Neoadjuvant docetaxel, oxaliplatin and S‑1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902) protocol of a multi‑center, phase II study

Protocol of OGSG 1901 a phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S − 1 therapy

Three-Year Outcomes of a Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601)

A phase II study of S‑1 therapy for patients with advanced and recurrent esophageal cancer resistant or intolerable to fluorouracil, platinum, and taxane therapy (OGSG 1404)

Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory tofluoropyrimidine-and platinum-based chemotherapy　(OGSG1201)

Phase II study of panitumumab monotherapy in chemotherapy-naïve frail or elderly patients with unresectable, RAS wild type colorectal cancer （OGSG 1602）